Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $10.59M | $8.08M | $8.61M | $3.64M | N/A | N/A |
| Cost of Revenue | $2.06M | $1.96M | $841.00K | N/A | $13.00K | $6.00K |
| Gross Profit | $8.53M | $6.13M | $7.77M | $3.64M | $-13.00K | $-6.00K |
| Gross Margin | 80.54% | 75.81% | 90.23% | 100.00% | 0.00% | 0.00% |
| Operating Expenses | $107.38M | $79.11M | $74.86M | $36.57M | $4.83M | $3.77M |
| Operating Income | $-98.85M | $-72.98M | $-67.09M | $-32.93M | $-4.84M | $-3.77M |
| Operating Margin | -933.58% | -902.87% | -779.04% | -905.39% | 0.00% | 0.00% |
| Net Income | $-68.99M | $-58.29M | $-63.06M | $-32.67M | $-6.78M | $-4.24M |
| Net Margin | -651.62% | -721.18% | -732.22% | -898.32% | 0.00% | 0.00% |
| EPS (Basic) | $-1.28 | $-1.32 | $-1.52 | $-0.79 | $-0.16 | $-0.10 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |